Pulse Biosciences (NASDAQ:PLSE) Shares Up 5.1% Following Insider Buying Activity

Key Points

• Pulse Biosciences shares rose 5.1% to about $49.98 after COO Liane Rae Teplitsky bought roughly $100,000 of stock across two transactions, nearly doubling her direct holdings.
• Analyst sentiment is mixed but leans positive: four analysts rate the stock Buy and one rates it Sell, resulting in a consensus “Moderate Buy” rating and a $45.25 average price target.
• The clinical-stage company continues to report weak financial results, including a quarterly EPS loss of $0.36 versus an expected $0.29 loss and revenue of $0.43 million versus $0.53 million expected; institutional investors own 76.95% of shares.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) was up 5.1% during mid-day trading on Monday after an insider bought additional shares in the company. The company traded as high as $50.09 and last traded at $49.98. Approximately 289,583 shares traded hands during trading, a decline of 17% from the average session volume of 347,447 shares. The stock had previously closed at $47.57.

Specifically, COO Liane Rae Teplitsky bought 1,034 shares of the business's stock in a transaction dated Friday, August 28th. The shares were purchased at an average cost of $48.35 per share, with a total value of $49,993.90. Following the completion of the purchase, the chief operating officer owned 2,070 shares in the company, valued at approximately $100,084.50. The trade was a 99.81% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Liane Rae Teplitsky purchased 1,036 shares of Pulse Biosciences stock in a transaction dated Wednesday, August 26th. The shares were bought at an average price of $48.23 per share, with a total value of $49,966.28. Following the completion of the acquisition, the chief operating officer directly owned 1,036 shares of the company's stock, valued at approximately $49,966.28. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Needham & Company LLC started coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They issued a "buy" rating and a $58.00 price target on the stock. Oppenheimer reaffirmed an "outperform" rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Mizuho set a $45.00 target price on shares of Pulse Biosciences in a research note on Monday, August 10th. Wall Street Zen upgraded shares of Pulse Biosciences from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.25.

Pulse Biosciences Stock Up 5.1%

The stock has a market capitalization of $3.46 billion, a PE ratio of -42.36 and a beta of 1.61. The firm's fifty day moving average price is $35.38 and its two-hundred day moving average price is $27.02.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The company had revenue of $0.43 million during the quarter, compared to analysts' expectations of $0.53 million. As a group, analysts predict that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Hedge Funds Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE lifted its holdings in Pulse Biosciences by 8.2% in the first quarter. Bank of America Corp DE now owns 866,061 shares of the company's stock valued at $18,698,000 after acquiring an additional 65,884 shares during the period. Panoramic Capital LLC purchased a new position in Pulse Biosciences in the second quarter worth about $2,719,000. Cetera Investment Advisers bought a new stake in shares of Pulse Biosciences during the 1st quarter valued at about $387,000. Formula Growth Ltd. bought a new stake in shares of Pulse Biosciences during the 2nd quarter valued at about $832,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Pulse Biosciences during the 2nd quarter valued at about $290,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source